Kidron Capital is a specialist early-stage healthcare venture firm investing in companies where sex-specific biology, unmet clinical need, and inefficient capital allocation create overlooked opportunities across devices, diagnostics, digital health, care delivery, and therapeutics.
Women's health is entering a new phase.
The category is moving beyond narrow reproductive health and consumer wellness into higher-acuity areas of medicine, including therapeutics, precision devices, diagnostics, and specialty care. At the same time, strategic acquirers are increasingly looking for pipeline renewal and differentiated growth in areas where female biology matters.
"Kidron Capital was built to invest into this inflection point with specialist focus, disciplined healthcare diligence, and access across the US, Europe, and Israel."
We invest with a specialist lens across the full spectrum of women's health.
We invest across conditions unique to women, diseases that affect women differently, and health needs that disproportionately impact women — broad enough to capture major opportunities, but disciplined enough to remain clinically coherent.
We start with the underlying biology: where female physiology changes disease risk, diagnosis, progression, treatment response, or care delivery. This allows us to identify women's health opportunities that generalist healthcare investors may overlook.
We evaluate each opportunity through evidence, mechanism, regulatory pathway, intellectual property, reimbursement logic, adoption barriers, and strategic exit relevance — not through thematic enthusiasm alone.
We invest across therapeutics, medical devices, diagnostics, digital health, healthcare services, and consumer health — with a consistent focus on scalable value creation.
With deep networks across the US, Europe, and Israel, we are positioned to source differentiated opportunities and support companies across major healthcare markets.
We invest in companies addressing clinically important, commercially significant opportunities across women's health.
A cross-border GP team built for women's health investing
Kidron is led by two healthcare investors with presence across Silicon Valley, Boston, Tel Aviv, Europe, and Israel. Together, the GPs combine women's health specialization, clinical and scientific diligence, venture investing, fund formation, transaction experience, and active portfolio governance.
Together, the GPs combine scientific diligence, venture judgment, cross-border sourcing, and active portfolio support across the women's health ecosystem.
We welcome conversations with founders, investors, and strategic partners working in or around women's health.
Important notice: This website is provided for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities. Any offering of fund interests will be made only to qualified/eligible investors by means of confidential offering documents and in accordance with applicable law. The information herein is believed to be reliable but is not guaranteed and should not be relied upon as a promise or representation of future performance. Past performance is not indicative of future results.
